What the FDA labels say about taking them together
Amiloride and valsartan
Valsartan's FDA label of August 5, 2026 names amiloride in its drug interactions section; amiloride's label does not name valsartan itself but warns about its class (ARBs (angiotensin II receptor blockers)). The valsartan label: “Concomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase …”
Check it at the source: the amiloride FDA label on DailyMed (effective May 5, 2023, Padagis US LLC); the valsartan FDA label on DailyMed (effective August 5, 2026, Macleods Pharmaceuticals Limited).
What does the amiloride label say about valsartan?
Amiloride's label does not name valsartan itself; it warns about its class (ARBs (angiotensin II receptor blockers)):
Amiloride label, warningsThe risk of hyperkalemia may be increased when potassium-conserving agents, including amiloride HCl, are administered concomitantly with an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist, cyclosporine or tacrolimus. (See PRECAUTIONS, Drug Interactions .) Warning signs or symptoms of hyperkalemia include paresthesias, muscular weakness, fatigue, flaccid paralysis of the extremities, bradycardia, shock, and ECG abnormalities.
Amiloride label, drug interactionsDrug Interactions When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist, cyclosporine or tacrolimus, the risk of hyperkalemia may be increased.
Source: FDA drug label (amiloride hydrochloride), Padagis US LLC, effective May 5, 2023 (SPL set 2b70cf0c-45be-428f-b396-5001ed4e30fc), via openFDA; the full label on DailyMed
What does the valsartan label say about amiloride?
Valsartan label, drug interactionsConcomitant use of valsartan with other agents that block the renin-angiotensin system, potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, salt substitutes containing potassium or other drugs that may increase potassium levels (e.g., heparin) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine.
Source: FDA drug label (Valsartan), Macleods Pharmaceuticals Limited, effective August 5, 2026 (SPL set 251ccff4-bf86-453b-9d1c-e3c1ecfd3a46), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Which combination products and biosimilars carry the same label text?
Their labels quote the same sentences for their ingredient; each has its own page with its own label dates.
Both medicines on the record
| Amiloride | Valsartan | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure | High blood pressure, Heart failure |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.190 per tablet 5 mg tablet | $0.0963 per tablet 40 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once